Novartis is making two investments in new radiopharmaceutical manufacturing sites in the US. The Swiss pharmaceutical giant will open a third US radioligand plant in Carlsbad, California, to serve the ...
(ITM), a leading radiopharmaceutical biotech company, today announced its participation in two upcoming industry investor ...
Radioligand therapies (RLTs) have received prominent attention from major pharmaceutical companies in treating prostate ...
The trial compares Eli Lilly’s lutetium zadavotide guraxetan with Astellas’s Xtandi (enzalutamide) or Janssen’s Zytiga ...
Pharmaceutical heavyweights like Bristol Myers Squibb, AstraZeneca, and Eli Lilly are betting big on radiopharmaceuticals, ...
Bristol Myers Squibb, AstraZeneca, Eli Lilly and other drug companies have invested some $10 billion on promising cancer ...
Despite the analysts’ downbeat assessment, Oliver Sartor, M.D., Director of Radiopharmaceutical Trials and Professor of ...
Bayer is targeting a broader use of Nubeqa in metastatic hormone-sensitive prostate (mHSPC) cancer with a combination free of ...
Sanofi agreed to pay up to 320 million euros ($352.4 million) to U.S. company RadioMedix and the biotechnology subsidiary of nuclear-fuel supplier Orano to license a potential treatment for rare ...
Just two years into its existence, radioisotope producer PanTera has drawn 93 million euros ($102.5 million) in an ...
The tumor-seeking radiopharmaceuticals are charting a new course in oncology, with promise for targeted treatments with fewer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback